| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014PNAS..11113373R |
| P356 | DOI | 10.1073/PNAS.1404848111 |
| P932 | PMC publication ID | 4169907 |
| P698 | PubMed publication ID | 25187556 |
| P5875 | ResearchGate publication ID | 265344346 |
| P50 | author | Adam J. Krieg | Q42934311 |
| Erinn B. Rankin | Q43206012 | ||
| Katherine C Fuh | Q84451503 | ||
| Amato J. Giaccia | Q110591782 | ||
| P2093 | author name string | Håkan Axelson | |
| Edward L LaGory | |||
| David Lindgren | |||
| Elizabeth C Finger | |||
| Anh N Diep | |||
| Laura Castellini | |||
| Mihalis S Kariolis | |||
| Andy Chan | |||
| Kartik Viswanathan | |||
| Yu R Miao | |||
| P2860 | cites work | The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis | Q22009936 |
| HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing | Q24291102 | ||
| Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site | Q24309038 | ||
| Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. | Q43228829 | ||
| Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma | Q44378605 | ||
| Characterization of the invasive and metastatic phenotype in human renal cell carcinoma | Q44673611 | ||
| Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. | Q45945576 | ||
| First Axl inhibitor enters clinical trials | Q85717127 | ||
| Inhibition of Transcription Elongation by the VHL Tumor Suppressor Protein | Q24336629 | ||
| Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C | Q24336712 | ||
| The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins | Q24564802 | ||
| Hypoxia-inducible factors in physiology and medicine | Q27013770 | ||
| HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression | Q27025886 | ||
| Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation | Q27860876 | ||
| Axl is essential for VEGF-A-dependent activation of PI3K/Akt | Q28116976 | ||
| The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Q28266682 | ||
| Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1 | Q28282227 | ||
| Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal | Q28288215 | ||
| Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase | Q28506124 | ||
| Purification and characterization of hypoxia-inducible factor 1 | Q28678375 | ||
| Identification of the von Hippel-Lindau disease tumor suppressor gene | Q29618644 | ||
| A renaissance for SRC | Q30014833 | ||
| HIF1α and HIF2α independently activate SRC to promote melanoma metastases | Q30539170 | ||
| Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma | Q33514834 | ||
| Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth | Q33558169 | ||
| The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells | Q33959078 | ||
| TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer | Q34794927 | ||
| HGF-independent potentiation of EGFR action by c-Met | Q35078530 | ||
| Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors | Q35927501 | ||
| AXL is an essential factor and therapeutic target for metastatic ovarian cancer | Q36127308 | ||
| Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer | Q36128435 | ||
| Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. | Q36518228 | ||
| A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition. | Q37227510 | ||
| Treatment selection in metastatic renal cell carcinoma: expert consensus | Q37999655 | ||
| Hypoxia-inducible factor-1alpha: molecular-targeted therapy for hepatocellular carcinoma | Q38003459 | ||
| Pathways and targets in hepatocellular carcinoma | Q38062022 | ||
| Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma | Q38122564 | ||
| Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. | Q38315198 | ||
| A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma | Q39532016 | ||
| The human receptor tyrosine kinase Axl gene--promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation | Q39975842 | ||
| Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. | Q40296387 | ||
| Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. | Q40633683 | ||
| Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways | Q40655882 | ||
| Tumour suppression by the human von Hippel-Lindau gene product | Q41320477 | ||
| Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). | Q42802867 | ||
| P433 | issue | 37 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 13373-13378 | |
| P577 | publication date | 2014-09-03 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET | |
| P478 | volume | 111 |
| Q41839294 | A comprehensive analysis of cancer-driving mutations and genes in kidney cancer |
| Q90148023 | AXL as a Target in Breast Cancer Therapy |
| Q38914744 | AXL as a modulator of sunitinib response in glioblastoma cell lines |
| Q35843071 | AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas |
| Q37684598 | AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer |
| Q39139917 | AXL receptor tyrosine kinase as a therapeutic target in NSCLC. |
| Q52659572 | Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastoma. |
| Q35949450 | Anti-Tumor Effects of Second Generation β-Hydroxylase Inhibitors on Cholangiocarcinoma Development and Progression. |
| Q38936702 | Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer? |
| Q90345202 | Blockade of Stromal Gas6 Alters Cancer Cell Plasticity, Activates NK Cells, and Inhibits Pancreatic Cancer Metastasis |
| Q64060174 | C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas |
| Q36281483 | Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. |
| Q39005403 | Cabozantinib for the treatment of renal cell carcinoma |
| Q28072166 | Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience |
| Q26741450 | Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy |
| Q89704881 | Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor |
| Q47116036 | Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation |
| Q34495684 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma |
| Q38859789 | Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. |
| Q52650529 | Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. |
| Q37672483 | Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma |
| Q101216963 | Clear cell renal cell carcinoma ontogeny and mechanisms of lethality |
| Q92310011 | Collagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer Metastasis |
| Q52611170 | Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma. |
| Q94686561 | Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms |
| Q47177700 | Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression |
| Q91659317 | Does Axl have potential as a therapeutic target in pancreatic cancer? |
| Q60950078 | Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics |
| Q92669315 | Engineered AXL-ECD-Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration |
| Q49550673 | Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib. |
| Q31155755 | For robust big data analyses: a collection of 150 important pro-metastatic genes |
| Q94465946 | Gas6 expression is reduced in advanced breast cancers |
| Q50862689 | Gas6-Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor-progressive advantages. |
| Q38763966 | Gene of the month: Axl. |
| Q38772267 | Giving AXL the axe: targeting AXL in human malignancy |
| Q36557240 | Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways |
| Q45073629 | HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo |
| Q92686647 | Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL |
| Q47893488 | Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe? |
| Q37234734 | Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer |
| Q55419613 | Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel-Lindau-Deficient Renal Cancer. |
| Q39456881 | Hypoxia-Inducible Factors: Master Regulators of Cancer Progression |
| Q26749159 | Hypoxic control of metastasis |
| Q90145023 | IDH2 reprograms mitochondrial dynamics in cancer through a HIF-1α-regulated pseudohypoxic state |
| Q28077444 | Implications of Hypoxia in Breast Cancer Metastasis to Bone |
| Q37545045 | Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies |
| Q50113702 | Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer |
| Q33580494 | KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage |
| Q39157476 | Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies |
| Q100425500 | Kidney Cancer: An Overview of Current Therapeutic Approaches |
| Q28072503 | Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response |
| Q41082549 | LncRNA HOTAIR regulates HIF-1α/AXL signaling through inhibition of miR-217 in renal cell carcinoma |
| Q89726319 | LncRNA XIST modulates HIF-1A/AXL signaling pathway by inhibiting miR-93-5p in colorectal cancer |
| Q64081694 | MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression |
| Q49953442 | Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma |
| Q47106713 | MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines |
| Q92667817 | Metabolic Profiling Reveals a Dependency of Human Metastatic Breast Cancer on Mitochondrial Serine and One-Carbon Unit Metabolism |
| Q41600499 | Molecular analysis of alternative transcripts of equine AXL receptor tyrosine kinase gene |
| Q37620907 | New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy |
| Q54990172 | New treatment options for metastatic renal cell carcinoma. |
| Q37233198 | Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase |
| Q36544445 | Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome |
| Q38868038 | Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma |
| Q88607647 | Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001) |
| Q54115562 | Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma. |
| Q45329617 | Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma |
| Q26796405 | Progress toward overcoming hypoxia-induced resistance to solid tumor therapy |
| Q41847773 | Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL. |
| Q64891848 | Qigesan reduces the motility of esophageal cancer cells via inhibiting Gas6/Axl and NF-κB expression. |
| Q47645332 | Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. |
| Q89700531 | Redox regulation in tumor cell epithelial-mesenchymal transition: molecular basis and therapeutic strategy |
| Q39157961 | Renal cell carcinoma: molecular characterization and evolving treatment paradigms. |
| Q37541688 | Reprogramming the immunological microenvironment through radiation and targeting Axl. |
| Q36545062 | Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis. |
| Q89393258 | Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies |
| Q90493724 | S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma |
| Q91320660 | SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth |
| Q96811967 | Sequencing Therapies for Metastatic Renal Cell Carcinoma |
| Q41940444 | Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity |
| Q57071032 | Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date |
| Q38451761 | Sunitinib activates Axl signaling in renal cell cancer. |
| Q53814929 | TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition. |
| Q90625345 | Target-Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model-Informed Dose Selection for the First-in-Human Study of AVB-S6-500 |
| Q38835745 | Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma |
| Q64253749 | Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys" |
| Q92434912 | Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma |
| Q26767351 | Targeting hypoxic response for cancer therapy |
| Q64951234 | Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation. |
| Q100455154 | Targeting the HIF2-VEGF axis in renal cell carcinoma |
| Q28068756 | The Receptor Tyrosine Kinase AXL in Cancer Progression |
| Q54298179 | The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. |
| Q38950573 | The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma |
| Q39042140 | The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor |
| Q93380660 | Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer |
| Q92372105 | Therapeutic Sequencing in Metastatic Renal Cell Carcinoma |
| Q61810968 | Transcatheter arterial embolization combined with hypoxia-replicative oncolytic adenovirus perfusion enhances the therapeutic effect of hepatic carcinoma |
| Q64103293 | Vitamin K Dependent Proteins in Kidney Disease |
| Q64083065 | p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts |
| Q94569427 | p85β regulates autophagic degradation of AXL to activate oncogenic signaling |
Search more.